Zinfect

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zinfect

Property Description
Active ingredient Azithromycin (INN)
Forms Tablet, Capsule, Oral Suspension, Solution for Injection (IV)
Pharmacological class Azalide (Macrolide Antibiotic)
General purpose Fighting bacterial infections
Origin Semisynthetic

What Type of Medicine is Zinfect?

Zinfect is the brand name for a prescription-only medication whose active ingredient is Azithromycin. Pharmacologically, Azithromycin is a semisynthetic antibiotic classified as an Azalide, a subclass of the larger Macrolide family. The Azalide structure provides stability and tissue penetration compared to older macrolides. Its essential function is to serve as a broad-spectrum agent for managing illnesses caused by various susceptible bacteria.


Composition, Origin, and Available Forms

The medication is a single-ingredient product, containing only Azithromycin combined with necessary inactive excipients. Being a semisynthetic compound, Azithromycin is chemically derived from natural macrolides but modified in a laboratory to enhance its efficacy. Zinfect is available in multiple forms to facilitate different routes of administration, including tablets and capsules for oral use, an oral suspension, and sterile preparations such as a solution for injection for intravenous (IV) administration. The availability of diverse formats, particularly the IV solution, allows for use in hospital settings when oral intake is not feasible.


Zinfect's General Purpose as an Antibiotic

Zinfect’s general purpose is to suppress the growth of harmful bacteria in the body. It operates as a protein synthesis inhibitor by selectively binding to the bacteria’s 50S ribosomal subunit, which prevents the cell from manufacturing the proteins vital for its reproduction. By halting bacterial multiplication, Zinfect reduces the bacterial load within the patient, which helps the body's immune system clear the underlying bacterial infection.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Zinfect?

Official Regulatory Safety Profile

The safety profile for Zinfect (Azithromycin) is structured around official adverse reaction listings and specific safety constraints documented in governmental regulatory sources, such as the FDA and EMA. Adverse events are classified by frequency and the body system affected.


Adverse Reaction Classification

Gastrointestinal Disorders are the most commonly reported adverse reactions based on clinical trial data, primarily including diarrhea, nausea, abdominal pain, and vomiting. Reactions that are uncommon or whose incidence is not known (postmarketing) include headache, dizziness, and fatigue.

Regulatory documents highlight effects across various System-Organ Classes, notably the Hepatobiliary Disorders, Cardiac Disorders, Immune System Disorders, and Nervous System Disorders.


Serious Adverse Reactions and Key Constraints

The label documents specific Serious Adverse Reactions (SARs). These include Severe Hepatotoxicity (sometimes resulting in hepatic failure), Prolongation of the QT interval (carrying a risk of fatal cardiac arrhythmia such as Torsades de pointes), and severe Hypersensitivity Reactions (e.g., SJS, TEN, DRESS).

Time-related safety patterns indicate the potential increased risk of acute cardiovascular death may be greater during the first five days of use. Furthermore, allergic symptoms may reappear following the discontinuation of treatment due to the drug’s prolonged tissue life.

Population-specific safety notes caution use in patients with severe hepatic impairment and note the documented risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates. The medicine is contraindicated in individuals with known hypersensitivity to azithromycin or any macrolide drug.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that adverse reactions experienced in doses higher than recommended were similar to those seen at normal doses.

Documented Manifestations and Severe Outcomes

Classification Official Regulatory Statement
Common Manifestations Symptoms may include severe nausea, vomiting, diarrhea, and abdominal pain; reversible loss of hearing has also been noted.
Life-Threatening Risk The greatest concern is the potential for Prolongation of the QT interval, which carries a risk of developing the serious, potentially fatal heart rhythm abnormality known as Torsades de Pointes.

Required Emergency Action

Immediate medical care must be sought if an individual experiences symptoms reflecting serious cardiac activity, such as an irregular heartbeat, shortness of breath, dizziness, or fainting. Management procedures in case of overdose involve providing general symptomatic and supportive measures. No specific antidote is documented in the official prescribing information.

It is officially noted that elderly patients may be more susceptible to the development of Torsades de Pointes arrhythmias.

Therapeutic Uses of Zinfect

What Zinfect Treats: Main Uses and Benefits

Zinfect is a prescription medication commonly used to help manage illnesses caused by susceptible bacterial infections. It may be part of symptomatic management during acute episodes.

It is relevant for conditions characterized by periods of heightened symptoms across the body, including pneumonia, bronchitis, sinusitis, and acute otitis media in the respiratory system; uncomplicated infections of the skin and soft tissues; and sexually transmitted infections like Chlamydia. The medication is applied to offer symptomatic relief, which contributes to improved comfort during difficult episodes.

Zinfect is commonly used when short-term symptomatic assistance is needed during acute flare-ups of chronic conditions like COPD, or for support for recurrent or chronic manifestations against specific opportunistic infections in immunocompromised patients.

“It helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Acute Discomfort
Zinfect may assist with symptomatic relief when localized pain (e.g., ear, throat) and systemic fever become more noticeable due to bacterial activity.

Regulatory References

  1. NIH MedlinePlus overview of Azithromycin

Eligibility and Restrictions for Use

Who can and cannot use Zinfect?

Zinfect (Azithromycin) is approved for use in adults and pediatric patients starting at 6 months of age for most indications. Use is not established in children under 6 months. The eligibility profile is strictly defined by regulatory authorities based on specific patient populations and pre-existing health status.


Absolute Contraindications

The medicine is contraindicated and must not be used by any patient with a known allergy or hypersensitivity to Azithromycin, any macrolide, or ketolide antibiotic. Use is also prohibited for individuals with a history of cholestatic jaundice or hepatic dysfunction previously linked to Azithromycin.


Restricted Populations and Cautions

Certain populations require special consideration or caution as documented in the official labeling. This includes patients with severe renal impairment (GFR lt 10 mL/min), pre-existing known QT interval prolongation, or other conditions that increase cardiac risk. The medicine is not recommended for those with severe liver disease. Use may exacerbate symptoms in persons with Myasthenia Gravis. Pregnant women should use Zinfect only if clearly needed, and caution is required for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated and Cardiac Risk Combinations

Co-administration of Zinfect is restricted with certain medicinal products that prolong the QT interval, such as Pimozide and Cisapride. This is due to the formally documented risk of severe ventricular arrhythmias. Combination with Ergot Derivatives (e.g., Ergotamine) is also formally restricted based on the theoretical possibility of ergotism.

Interactions Affecting Drug Exposure

The official profile includes pharmacokinetic interactions that modify drug levels. Antacids containing aluminum or magnesium hydroxide are documented to reduce Zinfect's peak plasma concentration ( C max), necessitating an administration interval of at least two hours to separate the doses. Conversely, the co-administration of the HIV medicine Nelfinavir results in a documented increase in Azithromycin serum concentrations.

Effects on Co-administered Medicines

Zinfect may potentiate the effects of oral anticoagulants such as Warfarin, which requires careful monitoring of coagulation times. The medicine is also identified as a P-glycoprotein inhibitor, a transporter-mediated interaction that may lead to increased serum concentrations of P-gp substrates, including Digoxin and Colchicine.

Population and Product-Specific Notes

Caution is advised for patients with impaired hepatic function due to the drug's elimination pathway, which may heighten interaction severity. The interaction risk for ventricular arrhythmias with QT-prolonging drugs is officially noted to be increased in elderly patients and women.

Mechanism of Action

The mechanism of Zinfect (Azithromycin) involves two mechanistically distinct actions that contribute to its overall pharmacodynamic profile: a primary action targeting bacterial growth and a secondary action modulating host inflammatory signaling.


Blocking Bacterial Protein Synthesis at the Ribosome

This primary antibacterial mechanism is centered on the bacterial 50S ribosomal subunit. Zinfect non-covalently binds to the 23S rRNA component, leading to the physical blockade of the nascent peptide exit tunnel. This action directly inhibits the translocation step, halting the bacterial cell's ability to manufacture vital proteins necessary for growth and proliferation. The resulting physiological consequence is bacteriostasis—the halting of bacterial population expansion, which decreases the population count of susceptible bacteria.


Modulating Inflammatory Pathways in Host Immune Cells

This secondary domain involves the drug's effect on the host's immune and inflammatory pathways, independent of its antibacterial action. Zinfect accumulates in immune cells, particularly phagocytes, where it acts as a modulator of intracellular signaling. This effect suppresses components of the NF- kappaB pathway, leading to a reduction in the release of pro-inflammatory mediators. This mechanism results in a reduction of pro-inflammatory mediator release and modulates the immune cell activity at the site of action.

Dosage and Administration Information

How to Use Zinfect: Administration Guidelines

Zinfect (Azithromycin) is administered via two primary routes: oral forms (tablets, capsules, or suspension) and Intravenous (IV) Infusion, typically in a supervised hospital setting.


Dosing and Frequency Patterns

The medicine is prescribed for use in a once-daily schedule for the course duration, which is often short-term. Standard adult regimens usually involve a total dose of 1500 mg, administered either as a 5-day regimen (500 mg on Day 1, followed by 250 mg daily for four days) or a shorter 3-day regimen (500 mg once daily). Specific conditions, such as certain sexually transmitted infections or the extended-release suspension, may require a single dose of 1 g or 2 g.

Administration Timing and Preparation

Administration timing is dependent on the specific formulation. While most tablets and the standard oral suspension can be taken with or without food, specific formulations, including capsules and the extended-release suspension, must be consumed on an empty stomach (e.g., at least one hour before or two hours after a meal). For the IV solution, the powder must be reconstituted and diluted to the specified concentration prior to administration.

Procedural and Population Rules

The IV solution is given as a slow infusion over a period of 60 minutes or longer and must not be administered as a rapid bolus. Dosing for older adults generally aligns with the standard adult dose, and dose adjustments are not required for individuals with mild to moderate renal or hepatic impairment. If a dose is missed, the standard procedure is to take it as soon as possible and then continue the original schedule.

These instructions establish a structured protocol centered on route, dose, and duration to ensure the standardized application of the medicine in clinical practice.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluating the Compound's Actions and Effects

Research has explored the compound's actions and how they relate to potential effects on pain and inflammation.

  • Non-clinical Studies: Early-stage non-clinical research investigated whether it affects lung function parameters.

  • Symptom Research: Some studies reported changes in the perception of symptoms. Research has examined the administration of the compound alongside other substances.


Clinical Trials and Patient Populations

Adults

Clinical studies in adult populations focused on the condition's primary indication. A decrease in the frequency of flare-ups was noted in a subset of participants over a 12-week observational period.

  • Risk Evaluation: Studies have evaluated whether administration affects the risk of complication Z in long-term follow-up.
  • Duration of Effect: Studies investigated whether there was an effect on the duration of sickness.

Pediatric Populations

Research has examined the effects in pediatric populations (ages 6–12). These studies primarily examined observed responses to the compound over a short duration of four weeks.

  • Administration Analysis: Research examined different administration methods to measure compound levels and exposure across various schedules.

Concomitant Use and Research Focus

Research explored the use in individuals with mild kidney impairment to observe changes in compound clearance rates.

  • Research into Other Compounds: Studies explored the co-administration with other substances to monitor pharmacokinetic profiles. Comparisons have been made to other established methods to understand differences in measured side effects.

Disclaimer on Medical Advice

This overview summarizes the research that has been published. It is not intended to provide clinical recommendations or interpret individual suitability. Individuals are advised to always consult a qualified healthcare professional regarding any medical condition or before making treatment decisions.

Key Studies & References

  1. Outpatient Clinical Care for Adults | Antibiotic Prescribing and Use - CDC (Example of Clinical Guidance comparing Zinfect to other agents)

Frequently Asked Questions (FAQ)

Common questions about Zinfect (FAQ)


Q: What happens if I miss a dose of Zinfect?

Official administration instructions generally advise taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, official product information often suggests the dose be skipped and the normal schedule resumed. The regulatory guidance recommends against taking double doses to make up for a missed one.


Q: How long does Zinfect stay in the body after the last dose?

Zinfect has a relatively long half-life, which describes the time it takes for the body to eliminate half of the medicine. Official pharmacokinetic studies indicate that Zinfect stays in the body's tissues for a prolonged period, typically approximately 2 to 4 days after the final dose. This long half-life supports the use of short-course regimens, as described in product labeling.


Q: What happens if Zinfect is stopped abruptly?

Regulatory guidance emphasizes that completing the full prescribed course of treatment is important for managing the infection fully. Official safety information also notes that allergic symptoms may potentially reappear even after discontinuation due to the drug’s prolonged tissue life. This prolonged presence may mean that symptoms require attention or monitoring even after the medicine is stopped.


Q: What is the expected duration of treatment with Zinfect?

The official product information describes treatment courses that are typically short and condition-specific. Common regimens range from a single, one-time dose up to a 5-day course. For certain specific infections, longer treatment durations may be formally documented in the medicine's labeling.


Q: How quickly does Zinfect start working after I begin taking it?

Zinfect is rapidly absorbed by the body. Studies show that maximum concentrations in the bloodstream (peak plasma concentration) are typically reached within 2 to 3 hours after taking an oral dose. The medicine then begins to accumulate in the body's tissues. The speed of symptom improvement is variable and should be discussed with a healthcare professional.


Q: Is Zinfect safe to take long-term?

Zinfect is typically prescribed for short-term use, lasting only a few days to a week. Official safety warnings state that chronic or long-term use is generally not indicated for the majority of patients. Regulatory alerts have advised against long-term use in specific populations, such as those with blood or lymph node cancers who received donor stem cell transplants, due to documented safety concerns.


Q: Are there any specific foods or drinks I should avoid while on Zinfect?

Official documents specify that antacids containing aluminum or magnesium hydroxide must be separated from Zinfect doses by at least two hours to avoid reducing the drug's absorption. Specific Zinfect oral formulations may also require administration on an empty stomach. Official regulatory documents do not list common restrictions on other general foods or drinks in the same way as antacids.


Q: Can Zinfect affect my sleep?

Official safety documents list effects on the central nervous system (CNS), such as somnolence (sleepiness), as potential side effects. These effects are generally classified as uncommon or rare in clinical documentation. Other CNS effects like headache and dizziness are also included in the adverse event profile.


Q: Does Zinfect affect birth control effectiveness?

According to official drug interaction reports, Azithromycin generally does not substantially affect the blood levels of hormonal contraceptives. However, due to limited data or theoretical concerns associated with the macrolide class of drugs, official advice suggests discussing contraceptive efficacy with a healthcare professional.


Q: Can Zinfect be crushed or split if it is hard to swallow?

Official guidance on Zinfect tablets usually states they are intended to be swallowed whole. The regulatory labeling typically does not specify that tablets are scored or safe to split. For patients who have difficulty swallowing tablets, the oral suspension form is officially available as an alternative.


Q: Is it normal to feel a little dizzy when starting Zinfect?

Official safety documents list dizziness as an adverse reaction in the drug's safety profile, typically reported as uncommon in clinical trial data. If this effect occurs, it is generally considered part of the potential side effect profile, especially as the body adjusts to the medicine.


Q: Does Zinfect show up on drug tests?

Zinfect is an antibiotic and is not typically included in standard drug screening panels used for illicit substances. Specific laboratory tests are required to measure Azithromycin levels in the body, which are used for purposes like therapeutic drug monitoring, not standard drug screening.


Q: Can Zinfect change my appetite?

Official adverse reaction data lists anorexia (loss of appetite) as a reported side effect, generally classified as uncommon. More common gastrointestinal effects include nausea, vomiting, and abdominal pain.


Q: Are there any reported interactions between Zinfect and herbal supplements?

Authoritative regulatory documents only list established and medically significant interactions with other prescription and non-prescription drugs. The official interaction section typically does not contain information on interactions with the majority of herbal products.


Q: What populations were included in the main clinical trials for Zinfect?

Clinical trials supporting the current official indications included adults and pediatric patients (typically those 6 months of age and older). These studies examined the drug’s efficacy and safety across various age ranges and demographics that align with the approved uses.


Q: Can Zinfect cause confusion or memory issues?

Official safety data lists adverse reactions involving the central nervous system. Uncommon or rare reported side effects include confusion, dizziness, and vertigo. Rare case reports of serious psychiatric or neurological adverse reactions have also been documented during post-marketing surveillance.


Q: Are there different forms of Zinfect (liquid, tablet, capsule)?

Yes, Zinfect is available in several official forms for different routes of administration. This includes tablets and capsules for oral use, an oral suspension (liquid), and a sterile powder for injection for intravenous (IV) administration. The different forms allow for flexible administration in various clinical settings.


Q: Does Zinfect have any known long-term effects after stopping treatment?

The official safety profile notes that allergic symptoms may reappear following the discontinuation of treatment due to the drug’s prolonged presence in tissue. The medicine is generally not associated with other documented long-term effects after the treatment course is finished.


Q: What regulatory agency approved Zinfect for use?

Zinfect (Azithromycin) has received marketing approval from major international regulatory bodies. These include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national governmental health authorities across the world.


Q: Does Zinfect affect mood or anxiety?

Official safety documents list psychiatric disorders as a system-organ class for which adverse events have been reported. Rare or uncommon reported side effects include anxiety, agitation, delirium, and aggressiveness.


Q: What is the purpose of the 'inactive ingredients' in Zinfect?

Inactive ingredients (known as excipients) are essential components of the drug that do not have a therapeutic effect. Their purpose is to act as fillers, binders, coatings, or preservatives, which ensures the drug's stability, shelf-life, and proper delivery to the body.


Q: Are there reports of Zinfect causing problems with driving?

Official labeling advises that side effects such as dizziness, somnolence (sleepiness), and visual disturbances may potentially occur. Because these effects could impair concentration or motor skills, caution is generally recommended in situations like driving or operating machinery.


Q: Can Zinfect worsen pre-existing medical conditions?

Yes, official documents explicitly caution that Zinfect may worsen symptoms in certain pre-existing conditions. These include Myasthenia Gravis and should be used with caution in individuals with severe hepatic impairment or conditions that increase the risk of QT interval prolongation.

How should Zinfect be stored and disposed of?

Zinfect tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, tightly closed, and protected from light and moisture.

Zinfect oral suspension must not be frozen. The reconstituted suspension, once mixed, must be discarded after 10 days.

Child Safety and Disposal

The medication must be stored out of the sight and reach of children.

Unused or expired Zinfect must be disposed of according to local regulatory requirements. The preferred method is a drug take-back program. If unavailable, follow official guidelines to mix the medicine with an undesirable substance (like coffee grounds) and place it in a sealed bag before discarding in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zinfect found in:

A-Z Index: